Novartis Makes $2B Bet on Breast Cancer Drug

Novartis invested $2 billion in a breast cancer drug from Synnovation's PI3Kα inhibitor. This investment aims to revive a triple therapy in breast cancer treatment. The drug targets the same area as one of Novartis' existing products.

NVS announced on March 20 that it will acquire Synnovation Therapeutics' PI3K-alpha inhibitor SNV4818 for $2 billion upfront, with up to $1 billion in additional milestone payments. The deal targets a next-generation approach for HR+/HER2- breast cancer patients, approximately 40% of whom carry PIK3CA mutations that the drug is designed to selectively target.

SNV4818, currently in a Phase 1/2 clinical study, is designed to hit mutant PI3K-alpha while sparing the wild-type protein, which could reduce the severe side effects that plagued earlier PI3K inhibitors and derailed previous treatment approaches. Novartis aims to use the drug to revive a triple-therapy combination strategy for breast cancer, pairing it with existing therapies in its oncology portfolio.

The acquisition is notable because Novartis already markets a product targeting the same biological pathway, but the company believes SNV4818's improved selectivity profile justifies the premium. The transaction is expected to close in H1 2026, subject to regulatory approvals. Rivals have been circling the mutant-selective PI3K space, making the deal a defensive play as much as an offensive one.